The World Health Organisation (WHO) has included Gilead Sciences' twice-yearly formulation of lenacapavir for pre-exposure ...

Lenacapavir, a long-acting injectable pre-exposure prophylaxis, has been recommended by the WHO to help protect high-risk ...

A breakthrough to reduce risk of HIV in adolescents and adults weighing at least 35 kg. WHO releases the new guidelines ...

LEN is the first long-acting PrEP product that requires only two injections per year, offering an appealing alternative to ...

The World Health Organization is now recommending that countries include an HIV drug newly approved for prevention, ...

In a major advancement in the global fight against HIV, the World Health Organization (WHO) has recommended the use of ...

A newly approved HIV prevention drug, lenacapavir, is set to be introduced in at least nine countries in early 2026, and Rwanda could be among the first to deploy it, government and World Health ...

As expected, the new recommendations that the World Health Organization (WHO) issued for HIV and sexually transmitted ...

The World Health Organization (WHO) has recommended the global use of injectable lenacapavir (LEN) twice a year to provide near-total ...

As HIV cases continue to rise in the Philippines, especially among the youth, a new global development may offer hope in ...

Lenacapavir, which was approved by the United States' Food and Drug Administration in June this year, is taken twice per year ...

SA has accepted an offer of just over R520-million from the Global Fund to Fight Aids, TB and Malaria to buy the twice-a-year ...